Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules

PLoS Pathogens

Volumn 8, Issue 10, 2012, Pages

  Johnson, Steven ^a   Tan, Lionel ^b   van der Veen, Stijn ^a   Caesar, Joseph ^a   Goicoechea De Jorge, Elena ^b   Harding, Rachel J ^a   Bai, Xilian ^c   Exley, Rachel M ^a   Ward, Philip N ^a   Ruivo, Nicola ^b   Trivedi, Kaushali ^b   Cumber, Elspeth ^a   Jones, Rhian ^a   Newham, Luke ^a   Staunton, David ^d   Ufret Vincenty, Rafael ^e   Borrow, Ray ^c   Pickering, Matthew C ^b   Lea, Susan M ^a   Tang, Christoph M ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Public Health Laboratory   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; WILD TYPE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BINDING SITES; COMPLEMENT FACTOR H; FEMALE; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEISSERIA MENINGITIDIS; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STRUCTURE, SECONDARY;

MURINAE; MUS MUSCULUS; NEISSERIA MENINGITIDIS;

EID: 84868100414     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002981     Document Type: Article

References (48)

1. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, et al. (2010) Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 50: 184-191.
2. van Deuren M, Brandtzaeg P, van der Meer JW, (2000) Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 13: 144-166.
3. Stephens DS, Greenwood B, Brandtzaeg P, (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369: 2196-2210.
4. Black S, Pizza M, Nissum M, Rappuoli R, (2012) Toward a meningitis-free world. Sci Trans Med 4: 123-125.
5. Tan LK, Carlone GM, Borrow R, (2010) Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 362: 1511-1520.
6. Bai X, Borrow R, (2010) Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Exp Rev Vacc 9: 1203-1217.
7. Finne J, Leinonen M, Makela PH, (1983) Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 2: 355-357.
8. Goldschneider I, Gotschlich EC, Artenstein MS, (1969) Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129: 1307-1326.
9. Gotschlich EC, Goldschneider I, Artenstein MS, (1969) Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state. J Exp Med 129: 1385-1395.
10. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, et al. (2009) Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458: 890-893.
11. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, et al. (2006) The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177: 501-510.
12. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, et al. (2004) Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72: 2088-2100.
13. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, et al. (2003) Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197: 789-799.
14. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, et al. (2009) Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200: 379-389.
15. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM, (2007) Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15: 233-240.
16. Soames CJ, Sim RB, (1997) Interactions between human complement components factor H, factor I and C3b. Biochem J 326: 553-561.
17. Zipfel PF, Hellwage J, Friese MA, Hegasy G, Jokiranta ST, et al. (1999) Factor H and disease: a complement regulator affects vital body functions. Mol Immunol 36: 241-248.
18. Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, et al. (2009) Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. J Biol Chem 284: 8738-8746.
19. Sharma AK, Pangburn MK, (1996) Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc Natl Acad Sci U S A 93: 10996-11001.
20. Carroll MC, (2004) The complement system in B cell regulation. Mol Immunol 41: 141-146.
21. Zipfel PF, Skerka C, Hellwage J, Jokiranta ST, Meri S, et al. (2002) Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans 30: 971-978.
22. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM, (2009) Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 199: 1360-1368.
23. Pajon R, Beernink PT, Granoff DM, (2012) Design of meningococcal factor h binding protein mutant vaccines that do not bind human complement factor h. Infect Immun 80: 2667-2677.
24. Day AJ, Willis AC, Ripoche J, Sim RB, (1988) Sequence polymorphism of human complement factor H. Immunogen 27: 211-214.
25. Zhang Q, Li Y, Tang CM, (2010) The role of the exopolyphosphatase PPX in avoidance by Neisseria meningitidis of complement-mediated killing. J Biol Chem 285: 34259-34268.
26. Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, et al. (2007) Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204: 1249-1256.
27. Ufret-Vincenty RL, Aredo B, Liu X, McMahon A, Chen PW, et al. (2010) Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. Invest Ophthalmol Vis Sci 51: 5878-5887.
28. Davila S, Wright VJ, Khor CC, Sim KS, Binder A, et al. (2010) Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 42: 772-776.
29. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, et al. (2011) Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 79: 970-981.
30. Seib KL, Serruto D, Oriente F, Delany I, Adu-Bobie J, et al. (2009) Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77: 292-299.
31. Chamot-Rooke J, Mikaty G, Malosse C, Soyer M, Dumont A, et al. (2011) Posttranslational modification of pili upon cell contact triggers N. meningitidis dissemination. Science 331: 778-782.
32. Lecuit M, Dramsi S, Gottardi C, Fedor-Chaiken M, Gumbiner B, et al. (1999) A single amino acid in E-cadherin responsible for host specificity towards the human pathogen Listeria monocytogenes. EMBO J 18: 3956-3963.
33. Johansson L, Rytkonen A, Bergman P, Albiger B, Kallstrom H, et al. (2003) CD46 in meningococcal disease. Science 301: 373-375.
34. Zarantonelli ML, Szatanik M, Giorgini D, Hong E, Huerre M, et al. (2007) Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect Immun 75: 5609-5614.
35. Kirkitadze MD, Barlow PN, (2001) Structure and flexibility of the multiple domain proteins that regulate complement activation. Immunol Rev 180: 146-161.
36. Beernink PT, Shaughnessy J, Ram S, Granoff DM, (2010) Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vacc Immunol 17: 1074-1078.
37. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, et al. (2011) A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186: 3606-3614.
38. Dormitzer PR, Ulmer JB, Rappuoli R, (2008) Structure-based antigen design: a strategy for next generation vaccines. Trends Biotech 26: 659-667.
39. Exley RM, Shaw J, Mowe E, Sun YH, West NP, et al. (2005) Available carbon source influences the resistance of Neisseria meningitidis against complement. J Exp Med 201: 1637-1645.
40. Prosser BE, Johnson S, Roversi P, Clark SJ, Tarelli E, et al. (2007) Expression, purification, cocrystallization and preliminary crystallographic analysis of sucrose octasulfate/human complement regulator factor H SCRs 6-8. Acta Crystallogr Sect F Struct Biol Cryst Commun 63: 480-483.
41. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P, (2004) The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 41: 355-367.
42. Kabsch W, (2010) Xds. Acta Crystallogr D 66: 125-132.
43. Winter G, Dokel S, Jones AK, Scheerer P, Krauss N, et al. (2010) Crystallization and preliminary X-ray crystallographic analysis of the [NiFe]-hydrogenase maturation factor HypF1 from Ralstonia eutropha H16. Acta Crystallogr Sect F Struct Biol Cryst Commun 66: 452-455.
44. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D 67: 235-242.
45. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystal 40: 658-674.
46. Cowtan K, (2006) The Buccaneer software for automated model building. 1. Tracing protein chains. Acta Crystallogr D 62: 1002-1011.
47. Bricogne G BE, Brandl M, Flensburg C, Keller P, Paciorek W, et al. (2011) BUSTER version X.Y.Z. Cambridge: Global Phasing Ltd.
48. Emsley P, Lohkamp B, Scott WG, Cowtan K, (2010) Features and development of Coot. Acta Crystallogr D 66: 486-501.